This presentation reports interim results from an ongoing prospective study of the effects of Lipiflow on Lipid Layer Thickness (LLT), Tear Osmolarity, and subjective dry-eye symptoms (OSDI). Our understanding of Meibomian Gland Dysfunction suggests that treatment with Lipiflow should tend to increase LLT, decrease tear osmolarity, and improve subjective symptoms. However, so far we have found no significant changes in LLT or tear osmolarity, and only modest improvements in OSDI.
View More Presentations from SYM-304
This presentation is from the session "SYM-304: Highlights From the Military Refractive Surgery Safety & Standards Symposium held in San Diego in January, 2019" from the 2019 ASCRS Annual Meeting held on May 4-7, 2019 in San Diego, California.